Platelet and growth factor concentrations in activated platelet-rich plasma: a comparison of seven commercial separation systems

Kushida, Satoshi; Kakudo, Natsuko; Morimoto, Naoki; Hara, Tomoya; Ogawa, Tomoya; Mitsui, Toshihito; Kusumoto, Kenji

doi:10.1007/s10047-014-0761-5

Cited by 123 publications

(106 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The production of PRP using a Selphyl device, described in the Kushida et al 16 study, furnished 0.21 billion injected platelets, whereas the Magellan device characterised in the same study furnished 5.43 billion injected platelets, corresponding to a 25-fold increase. The complete data are provided in table 2.…”

Section: Introductionmentioning

confidence: 93%

DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices

Magalon

Château

Bertrand

et al. 2016

BMJ Open Sport Exerc Med

191

150

View full text Add to dashboard Cite

Background/aimSignificant biological differences in platelet-rich plasma (PRP) preparations have been highlighted and could explain the large variability in the clinical benefit of PRP reported in the literature. The scientific community now recommends the use of classification for PRP injection; however, these classifications are focused on platelet and leucocyte concentrations. This presents the disadvantages of (1) not taking into account the final volume of the preparation; (2) omitting the presence of red blood cells in PRP and (3) not assessing the efficiency of production.MethodsOn the basis of standards classically used in the Cell Therapy field, we propose the DEPA (Dose of injected platelets, Efficiency of production, Purity of the PRP, Activation of the PRP) classification to extend the characterisation of the injected PRP preparation. We retrospectively applied this classification on 20 PRP preparations for which biological characteristics were available in the literature.ResultsDose of injected platelets varies from 0.21 to 5.43 billion, corresponding to a 25-fold increase. Only a Magellan device was able to obtain an A score for this parameter. Assessments of the efficiency of production reveal that no device is able to recover more than 90% of platelets from the blood. Purity of the preparation reveals that a majority of the preparations are contaminated by red blood cells as only three devices reach an A score for this parameter, corresponding to a percentage of platelets compared with red blood cells and leucocytes over 90%.ConclusionsThese findings should provide significant help to clinicians in selecting a system that meets their specific needs for a given indication.

show abstract

Section: Introductionmentioning

confidence: 93%

DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices

Magalon

Château

Bertrand

et al. 2016

BMJ Open Sport Exerc Med

191

150

View full text Add to dashboard Cite

show abstract

“…Furthermore, different preparation methods aggravate the wide variability in the composition of different PRP products [13]. Kushida et al [14] reported great differences in growth factor concentrations in the activated PRP of seven commercial preparation systems. Mazzocca et al [15] examined three different PRP preparation methods regarding the concentration of platelets, red and white blood cells, and growth factors.…”

Section: Introductionmentioning

confidence: 99%

Platelet-Rich Plasma in Tissue Engineering: Hype and Hope

Lang

Loibl²,

Herrmann³

2018

Eur Surg Res

View full text Add to dashboard Cite

Background: Platelet-rich plasma (PRP) refers to an enriched platelet suspension in plasma. In addition to the clinical application of PRP in the context of various orthopedic diseases and beyond, PRP and platelet lysate (PL) have been in focus in the field of tissue engineering. In this review, we discuss the application of PRP as a cell culture supplement and as part of tissue engineering strategies, particularly emphasizing current hurdles and ambiguities regarding the efficacy of PRP in these approaches. Summary: As a putative autologous replacement for animal-derived supplements such as fetal calf serum (FCS), PRP has been applied as cell culture supplement for the expansion of stem and progenitor cells for tissue engineering applications and cell therapies. Attributed to the high content of growth factors in platelets, PRP has been shown to promote cell growth, which was mostly superior to standard cultures supplemented with FCS, while the differentiation capacity of progenitor cells seems not to be affected. However, it was also suggested that cultivation of cells with PRP significantly alters the protein expression profile in cells in comparison to FCS, indicating that the influence of PRP on cell behavior should be thoroughly investigated. Moreover, different PRP preparation methods and donor variations have to be considered for the use of PRP under good manufacturing practice conditions. PRP has been used for various tissue engineering applications in the context of bone, cartilage, skin, and soft tissue repair, where most studies were conducted in the field of bone tissue engineering. These approaches take either advantage of the release of chemoattractive, angiogenic, proliferative, and putatively pro-regenerative growth factors from PRP, and/or the hydrogel properties of activated PRP, making it suitable as a cell delivery vehicle. In many of these studies, PRP is combined with biomaterials, cells, and in some cases recombinant growth factors. Although the experimental design often does not allow conclusions on the pro-regenerative effect of PRP itself, most publications report beneficial effects if PRP is added to the tissue-engineered construct. Furthermore, it was demonstrated that the release of growth factors from PRP may be tailored and controlled when PRP is combined with materials able to capture growth factors. Key Messages: Platelet-derived preparations such as PRP and PL represent a promising source of autologous growth factors, which may be applied as cell culture supplement or to promote regeneration in tissue-engineered constructs. Furthermore, activated PRP is a promising candidate as an autologous cell carrier. However, the studies investigating PRP in these contexts often show conflicting results, which most likely can be attributed to the lack of standardized preparation methods, particularly with regard to the platelet content and donor variation of PRP. Ultimately, the use of PRP has to be tailored for the individual application.

show abstract

“…PRP clearly has a concentration-dependent effect, with standardization of PRP preparation still unavailable. These factors and the numerous available protocols [74] can explain the contradictory results that have been obtained. More studies with a higher number of patients will be required to reach a consensus on the use of PRP at a defined concentration.…”

Section: Prp Enriched Graftsmentioning

confidence: 88%

Autologous Fat Grafting in the Breast: Critical Points and Technique Improvements

et al. 2015

View full text Add to dashboard Cite

show abstract

Platelet and growth factor concentrations in activated platelet-rich plasma: a comparison of seven commercial separation systems

Cited by 123 publications

References 18 publications

DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices

DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices

Platelet-Rich Plasma in Tissue Engineering: Hype and Hope

Autologous Fat Grafting in the Breast: Critical Points and Technique Improvements

Contact Info

Product

Resources

About